Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;39(7):733-735.
doi: 10.15537/smj.2018.7.21897.

Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study

Safana A Al-Rawi  1 , Basil O Saleh, Manwar A Al-Naqqash
Affiliations

Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study

Safana A Al-Rawi et al. Saudi Med J. 2018 Jul.

Abstract

Objectives: To investigate the role of serum anti müllerian hormone (AMH) pre-chemotherapy treatment levels in prediction of post-chemotherapy effect on the ovarian reserve of women with breast cancer.

Methods: This cohort prospective study was carried out at the Biochemistry Department, College of Medicine, University of Baghdad and at the Oncology Clinic, Oncology Teaching Hospital, Baghdad, Iraq. It included 58 women with regular menstrual cycle (25-45 years) who were newly diagnosed with breast cancer. The women were classified into 3 groups: GI: 30 women with breast cancer before starting chemotherapy, GII: the same 30 women of GI who finished 4 cycles of anthracycline chemotherapy (course 1) and GIII: which involved another 28 women who had finished both courses of chemotherapy, (course 1) and (course 2).

Results: The mean (±SEM) value of AMH levels was significantly decreased in GII and GIII when compared with GI (for both, p less than 0.0005). However, there was no significant difference in serum AMH levels between GII and GIII.

Conclusion: The measurement of serum AMH may be a useful biochemical marker of the chemotherapy extent induced ovarian reserve damage and the incidence of amenorrhea.

PubMed Disclaimer

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. - PubMed
    1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29. - PubMed
    1. Iraqi National Cancer Research Center. Brief historical introduction, establishing the breast & cervical cancer research unit and the Iraqi National Cancer Research Center/Program. Baghdad (Iraq): Iraqi National Cancer Research Center; 2013.
    1. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–4183. - PubMed
    1. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-mullerian hormone: above and beyond conventional ovarian reserve markers. Dis Markers. 2016;2016:5246217. - PMC - PubMed

MeSH terms